Nurix Therapeutics Inc
NRIX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.78B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.78 Billion |
|---|---|
| Enterprise Value | $1.78 Billion |
| Earnings per Share | $-3.05 |
| Beta | 1.82 |
| Outstanding Shares | 111,563,067 |
Return
| Return on Equity | 73.24% |
|---|---|
| Return on Assets | 55.06% |
| Return on Invested Capital | 65.35% |
Valuation & Multiples
| P/E Ratio | 10.68 |
|---|---|
| PEG | -1.45 |
| Price to Sales | 2.66 |
| Price to Book Ratio | 5.32 |
| Enterprise Value to Revenue | 2.54 |
| Enterprise Value to EBIT | 5.89 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 12, 2026
EPS Estimate
$-0.60
Consensus analyst estimateRevenue Estimate
$24.35 M
Consensus analyst estimateNext Earnings Call
Expected Date
January 27, 2027
EPS Estimate
$-0.46
Consensus analyst estimateRevenue Estimate
$287.86 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 32.69% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.15%▼ 105.16% |
|---|---|
| Total Invested | $30.32M▼ 98.94% |
| Investors Holding | 35▼ 183.00% |
About Nurix Therapeutics Inc
2,020 employees
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other ch...